Classical pharmacogenetics;Klassisk farmakogenetik

Ugeskrift for Laeger

Volumn 167, Issue 20, 2005, Pages 2143-2146

  Brøsen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLURIC ACID; 1 METHYLXANTHINE; 1,7 DIMETHYLURIC ACID; 5 ACETAMIDO 6 FORMYLAMINO 3 METHYLURACIL; CHOLINESTERASE; CODEINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DEBRISOQUINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; LANSOPRAZOLE; MEPHENYTOIN; NEUROLEPTIC AGENT; OMEPRAZOLE; PROGUANIL; PROTON PUMP INHIBITOR; SPARTEINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

ACETYLATION; DENMARK; DRUG ACTIVITY; ENZYME BLOOD LEVEL; ENZYME STRUCTURE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INHERITANCE; MALIGNANT HYPERTHERMIA; OXIDATION KINETICS; PHARMACOGENETICS; SHORT SURVEY;

ARYL HYDROCARBON HYDROXYLASES; CARRIER PROTEINS; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS;

EID: 20344384559     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. Andreasen PB, Froland A, Skovsted L et al. Diphenylhydantoin half-life in man and its inhibition by phenylbutazone: the role of genetic factors. Acta Med Scand 1973;193:561-4.
2. Rasmussen BB, Brix TH, Kyvik KO et al. The interindividual differences in the 3-demetnylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 2002;12:473-8.
3. Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fund Clin Pharmacol 2003;17:27-41.
4. Brøsen K. Individuelle variationer i lægemidlers oksidative metabolisme. Ugeskr Læger 1984;13:955-9.
5. http://www.imm.ki.se/CYPalleles /aug 2004.
6. Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of alleleic variations to the phenotype of drug response. Molecular Psychiatry 2004;9:442-73.
7. Klotz U, Schwab M, Treiber M. CYP2C19 polymorphism and proton pump inhibitors. Bas Clin Pharmacol Toxicol 2004;95:2-8.
8. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther D Monit 2004;25:180-5.
9. Brøsen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989;36:537-47.